Day: August 25, 2020

TORONTO, Aug. 25, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the nomination of newly-acquired subsidiary InTouch With Health’s (InTouch) digital pre-op solutions, Synopsis iQ, for an award at the Smarter Working Live 2020 Awards.As released on the 20th of August 2020, VitalHub recently acquired InTouch With Health. InTouch was established in 1999 and specialises in delivering IT-based patient flow management solutions to help hospitals and private healthcare providers increase organisational efficiency and deliver an improved patient experience. InTouch’s marquee pre-op assessment platform, Synopsis iQ, completely digitises the perioperative assessment journey, offering value, clarity and efficiency for the care team and patients.Synopsis iQ has been nominated for an award...

MONTREAL and BOCA RATON, Fla, Aug. 25, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of IMVEXXY® by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas1-4. IMVEXXY is an applicator-free, estradiol softgel vaginal capsule indicated for postmenopausal women who experience pain before, during or after sex. IMVEXXY (estradiol vaginal inserts) is marketed by TherapeuticsMD in the U.S. for the treatment of moderate to severe dyspareunia, a symptom of VVA,...

MONTRÉAL et BOCA RATON, Fla., 25 août 2020 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX : GUD) [« Knight »] et TherapeuticsMD, Inc. (NASDAQ : TXMD) [« TherapeuticsMD »], ont annoncé aujourd’hui l’approbation d’IMVEXXY® par Santé Canada. Au Canada, IMVEXXY   est indiqué pour le traitement de la dyspareunie post-ménopausique modérée à sévère, un symptôme de l’atrophie vulvo-vaginale (AVV). L’AVV est une affection courante, chronique et évolutive associée à la ménopause. Les symptômes courants de l’AVV comprennent la sécheresse, l’inconfort et la douleur dans les régions vaginales et vulvaires1-4. IMVEXXY est une capsule vaginale gélatineuse molle à base d’estradiol sans applicateur, indiquée pour les femmes postménopausées qui éprouvent des douleurs avant, pendant ou après les rapports sexuels. IMVEXXY (estradiol administré par...

VANCOUVER, British Columbia, Aug. 25, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality (AR) for eCommerce, AR learning applications, and AR-enhanced video conferencing and virtual events is pleased to announce it has hired SAP executive Eugen Winschel as Chief Operating Officer. Eugen was a Global Vice President business Leader at SAP, an expert in Artificial Intelligence (AI) and Next-Gen UX developer as well as innovative entrepreneur and intrapreneur.Winschel has an extensive track record of proven success. In his previous positions with SAP as Global Vice President, he completely transformed the size and experience for global and regional events, digitized the physical world with IoT technology, delivered the first Enterprise Artificial Intelligence...

YONKERS, New York, Aug. 25, 2020 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into an initial funding agreement with the Cystic Fibrosis Foundation to investigate the potential utility of DLAs against resistant Gram-negative pathogens which afflict Cystic Fibrosis (CF) patients. The first stage of the agreement will profile funding for the in vitro activity of ContraFect’s next product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa, and amurin peptides, against bacterial specimens obtained from CF patients at different...

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) — AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020 at 5:00 p.m. ET.A live webcast of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.About AlloVirAlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific...

3.8-point mean improvement on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale was statistically significant vs. placebo (p = 0.029)8.0-point mean improvement on Myasthenia Gravis Composite (MGC) scale was highly statistically significant vs. placebo (p = 0.006)Mean reductions in total IgG from baseline for the 340 mg and 680 mg cohorts were 59% and 76%, respectivelyIMVT-1401 was observed to be generally safe and well-tolerated with no serious adverse events (SAEs) and no withdrawals due to adverse events (AEs)Registration-enabling Phase 3 MG trial is expected to initiate in the first half of 2021NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced positive topline...

VANCOUVER, British Columbia, Aug. 25, 2020 (GLOBE NEWSWIRE) — Norseman Capital Ltd. (“Norseman” or the “Company”) (TSXV:NOC) announces that it intends to change its name (the “Name Change”) to “Norseman Silver Inc.”Completion of the Name Change is subject to the receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange. Pursuant to the provisions of the Business Corporations Act (British Columbia) and the articles of the Company, shareholder approval for the Name Change is not required, and consequently, the Company is not seeking shareholder approval for the Name Change.For further information, please contact:John W. BarrInterim Chief Executive OfficerT: + 61 0 418 912 885Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX...

SHENZHEN, China, Aug. 25, 2020 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (Nasdaq: XNET), a leading innovator in shared cloud computing and blockchain technology in China, today announced its unaudited financial results for the second quarter ended June 30, 2020.Total revenues were US$44.3 million, representing a decrease of 8.3% from the previous quarter.Cloud computing and other internet value-added services (“Cloud computing and other IVAS”) revenues were US$21.0 million, representing a decrease of 0.9% from the previous quarter.Subscription revenues were US$20.7 million, representing a decrease of 11.4% on a sequential basis.Online advertising revenues (consisting primarily of revenues from mobile advertising) were US$2.7 million, representing a decrease of 30.4% from the previous quarter.Gross profit was...

Please find attached our Financial Calendar 2020-21.AttachmentFinancial calendar 2020-21 RIAS